Noninsulin glucose-lowering agents currently used to treat T2D in the USA include biguanides, sulfonylureas, thiazolidinediones, -glucosidase inhibitors, meglitinides, dipeptidyl peptidase 4 inhibitors (DPP4is), sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists, bile acid sequestrants, dopamine-2 agonists, and amylin mimetics [3]
Together, glutathione and selenium work synergistically to help support cardiovascular health and overall wellbeing
Mean HbA 1c , HbA 1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study
you're investing in a clinical team and a structured pathway to success